Testing BBT001 for chronic hives
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You weigh no more than 125 kg (about 275 lbs).
- You have moderate to severe hives (a score of 16 or higher on a standard hives diary).
- You are taking a daily antihistamine at a stable dose.
- You have not had a herpes infection (like cold sores or shingles).
- If you have tried other biologic drugs (like omalizumab or dupilumab), you must have stopped them at least 5 half-lives before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental capsule (HS-10561) to see if it is safe and works for people with chronic spontaneous urticaria, which causes hives and itching without a clear trigger. If you have had hives for at least 6 months, you might be able to join.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This trial tests a new injectable medicine (JYB1904) to see if it can reduce itching and hives better than standard antihistamines alone. If you have chronic hives with no clear cause and still get symptoms despite taking antihistamines, this study may be an option for you.
This study tests a new medication called HRS-3095 to see if it can help people whose chronic hives (itchy welts) do not get better with standard allergy pills. It aims to reduce itching and wheals and improve quality of life.
This trial tests an experimental drug called HRS-3095 in healthy people to check its safety and how the body handles it. It may help find the right dose for future studies.
This trial tests a new oral medication called tacabrutideg (BGB-16673) for chronic spontaneous urticaria, a condition with frequent hives and itching. It aims to see how safe it is and how well it works, possibly offering a new option for people who still have symptoms despite antihistamines.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.